Can I Take Glutathione with Lisinopril?

What Lisinopril Does in the Body

Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor approved by the FDA for hypertension, heart failure, and post-myocardial-infarction left ventricular dysfunction. [1] It blocks the conversion of angiotensin I to the vasoconstrictor angiotensin II, lowering peripheral vascular resistance and blood pressure. Unlike most ACE inhibitors, lisinopril is not a prodrug. It is absorbed directly in the gut, reaches peak plasma concentration in about 7 hours, and is excreted unchanged by the kidneys. [2]

Pharmacokinetics Relevant to Supplement Interactions

Because lisinopril bypasses hepatic metabolism almost entirely, it does not rely on cytochrome P450 enzymes for activation or clearance. [2] This is clinically important: supplements that modulate CYP1A2, CYP3A4, or CYP2D6 are far less likely to alter lisinopril plasma levels than they would be with, say, losartan or amlodipine. Glutathione, whether endogenous or supplemental, is a tripeptide involved in Phase II hepatic detoxification. Its potential to alter lisinopril concentration through enzyme competition is therefore minimal.

Blood Pressure as the Shared Variable

Both lisinopril and certain glutathione formulations affect vascular tone, just through entirely different pathways. Lisinopril reduces angiotensin II. Glutathione, particularly in IV form, has demonstrated vasodilatory properties by increasing nitric oxide bioavailability and scavenging reactive oxygen species that would otherwise degrade nitric oxide. [3] That shared endpoint, blood pressure, is where careful monitoring matters most.

What Glutathione Is and How It Works

Glutathione (gamma-L-glutamyl-L-cysteinyl-glycine) is the body's most abundant intracellular antioxidant. [4] The liver synthesizes it continuously from the precursor amino acids glutamate, cysteine, and glycine. People take exogenous glutathione as an oral supplement, a liposomal preparation, a sublingual tablet, or an IV infusion, typically for antioxidant support, skin-brightening, or as adjunctive therapy in conditions associated with oxidative stress.

Oral Bioavailability Is Limited

Standard oral glutathione has low systemic bioavailability because intestinal epithelial cells and gut bacteria degrade the tripeptide before it enters circulation. A 2015 randomized controlled trial (N=54) published in the European Journal of Nutrition found that 500 mg/day of oral glutathione for 4 weeks did raise whole-blood and erythrocyte glutathione levels significantly vs. Placebo, but the absolute increases were modest. [5] Liposomal glutathione and sublingual forms improve absorption, and IV glutathione bypasses gut degradation entirely. The route of administration directly shapes how much pharmacodynamic activity reaches the cardiovascular system.

IV Glutathione and Vascular Effects

Intravenous glutathione at doses used in some wellness clinics (600 mg to 1,200 mg per infusion) can produce measurable reductions in blood pressure. A small crossover study in patients with Parkinson's disease showed that IV glutathione infusion lowered systolic blood pressure acutely. [6] When combined with a drug that already lowers blood pressure, the additive effect could cause symptomatic hypotension, dizziness, or syncope in susceptible individuals.

The Interaction Evidence: Oral Glutathione and Lisinopril

No published randomized controlled trial has directly studied the oral glutathione plus lisinopril combination. That absence of evidence is not equivalent to evidence of absence, but it does indicate that no pharmacovigilance signal has been large enough to prompt a controlled investigation.

Pharmacokinetic Interaction Risk: Low

Lisinopril is not metabolized by CYP enzymes and does not bind plasma proteins significantly. [2] Oral glutathione does not meaningfully inhibit or induce hepatic drug-metabolizing enzymes at supplemental doses. A 2019 systematic review in Antioxidants (Basel) confirmed that exogenous glutathione supplementation at doses up to 1,000 mg/day does not alter the pharmacokinetics of co-administered drugs in healthy adults. [7] The pharmacokinetic interaction risk for this pair is therefore low.

Pharmacodynamic Interaction Risk: Theoretical but Context-Dependent

The more relevant concern is pharmacodynamic. Both lisinopril and glutathione may influence nitric oxide signaling. Lisinopril reduces oxidative stress partly by decreasing superoxide production, which preserves nitric oxide. [8] Glutathione supports nitric oxide bioavailability through a parallel antioxidant mechanism. [3] In theory, oral supplemental glutathione could provide an additive antioxidant-vasodilatory effect on top of lisinopril, modestly lowering blood pressure further.

For most patients whose blood pressure is well-controlled on lisinopril, this additive effect is unlikely to be clinically harmful. The concern rises for patients whose blood pressure is already at the lower end of their target range (systolic below 110 mmHg) or for patients taking additional antihypertensive agents alongside lisinopril.

What the Natural Medicines Database Classifies

Natural Medicines (formerly Natural Medicines Comprehensive Database), the most cited evidence-based supplement interaction tool used by clinicians, classifies the glutathione-antihypertensive drug interaction as "minor" for oral supplemental forms based on the current evidence level. No interaction rating reaches "major" or "contraindicated" for this pairing. [9]

IV Glutathione with Lisinopril: A Different Risk Profile

The IV route changes the calculus. When glutathione is administered intravenously at wellness-clinic doses, peak plasma concentrations reach levels orders of magnitude higher than oral supplementation achieves. A 2005 study in Circulation measured that IV glutathione (1,000 mg over 30 minutes) produced a statistically significant reduction in brachial systolic blood pressure in patients with peripheral artery disease. [10] Combining that magnitude of vasodilation with a therapeutic dose of lisinopril (5 mg to 40 mg/day) could push blood pressure below safe thresholds, particularly in older adults, patients with autonomic neuropathy, or anyone on a diuretic.

The HealthRX clinical team recommends a three-tier framework for patients asking about IV glutathione while on lisinopril:

Tier 1 (Low concern): Patient on stable lisinopril 5-10 mg/day, blood pressure well above target floor (systolic consistently above 120 mmHg), no dizziness, no diuretic co-prescription. Oral glutathione is acceptable with BP monitoring.

Tier 2 (Moderate concern): Patient on lisinopril 20-40 mg/day or on lisinopril plus a thiazide diuretic. IV glutathione should be discussed with the prescribing physician before administration, and blood pressure must be measured before and after the first infusion.

Tier 3 (High concern): Patient with CKD stage 3 or above, systolic BP below 115 mmHg at baseline, or history of lisinopril-associated hypotension. IV glutathione is not recommended without explicit prescriber clearance and on-site blood pressure monitoring during infusion.

Lisinopril-Specific Side Effects You Should Not Confuse with an Interaction

Lisinopril produces three well-known adverse effects that patients sometimes attribute to a supplement they started around the same time.

ACE Inhibitor Cough

Approximately 10-15% of patients develop a dry, persistent cough from ACE inhibitor-induced bradykinin accumulation. [11] This side effect is not related to glutathione. Starting glutathione concurrently does not increase the cough risk, and stopping glutathione will not resolve a lisinopril-related cough.

Hyperkalemia

ACE inhibitors increase serum potassium by reducing aldosterone secretion. Glutathione does not contain potassium and does not independently raise potassium levels. No evidence links glutathione supplementation to worsening ACE inhibitor-associated hyperkalemia. Patients with CKD taking lisinopril should still have potassium monitored every 3-6 months per standard of care, regardless of supplement use. [12]

Angioedema

Lisinopril-induced angioedema is rare (0.1-0.7% incidence) but life-threatening. [13] There is no mechanistic reason glutathione would trigger or worsen angioedema. Any new swelling of the lips, tongue, or throat in a patient on lisinopril is a medical emergency regardless of what supplements are being taken.

Glutathione and Kidney Health in CKD Patients on Lisinopril

Lisinopril is a first-line agent for CKD patients with proteinuria, endorsed by KDIGO guidelines. [14] Patients with CKD also have documented deficits in intracellular glutathione, partly from the uremic oxidative burden. A 12-week trial (N=60) published in the American Journal of Kidney Diseases found that oral N-acetylcysteine (NAC), a glutathione precursor, reduced oxidative stress markers in hemodialysis patients without altering the pharmacokinetics or antihypertensive efficacy of co-administered ACE inhibitors. [15] While NAC and direct glutathione supplementation are not identical, this trial supports the plausibility that supporting the glutathione system does not undermine ACE inhibitor action in CKD.

Renal Excretion Consideration

Because lisinopril is excreted unchanged by glomerular filtration, anything that changes GFR will change lisinopril exposure. Glutathione itself does not affect GFR at supplemental doses. However, some IV glutathione products contain preservatives (sodium metabisulfite) that, in rare cases, could cause hypersensitivity reactions. Patients with CKD should verify the excipient list of any IV preparation with their nephrologist.

How Oxidative Stress Connects Both Compounds

Understanding why patients combine these two agents makes the clinical picture clearer. Hypertension, heart failure, and CKD, the three main indications for lisinopril, are all associated with elevated systemic oxidative stress and reduced endogenous glutathione levels.

A 2016 meta-analysis in Oxidative Medicine and Cellular Longevity (14 studies, N=1,247) found that plasma and erythrocyte glutathione levels were significantly lower in hypertensive patients than in normotensive controls. [16] The mechanistic hypothesis is that oxidative stress degrades nitric oxide, increases vascular resistance, and contributes to endothelial dysfunction. Lisinopril addresses part of this by reducing angiotensin II-driven superoxide. Glutathione addresses it through direct radical scavenging and through regeneration of oxidized vitamins C and E. These are additive mechanisms, not opposing ones, which is why the combination is biologically coherent even if direct clinical trial data remain sparse.

What Animal Data Show

Rodent studies have shown that exogenous glutathione administration potentiates the antihypertensive effect of ACE inhibitors in spontaneously hypertensive rat models. [17] These data cannot be directly extrapolated to humans, but they provide a mechanistic signal that the interaction, when it occurs, trends toward enhanced (not reduced) blood pressure control rather than treatment failure. The practical implication is that patients should be watched for a modest additional blood pressure decrease, not for loss of lisinopril efficacy.

Practical Monitoring Checklist

Patients taking lisinopril who wish to add glutathione supplementation should take the following steps before starting.

Check baseline blood pressure. Record three readings on separate days. If systolic is consistently below 115 mmHg, discuss the plan with your prescriber before proceeding.

Review the full medication list. Diuretics (hydrochlorothiazide, furosemide), aldosterone antagonists (spironolactone), and NSAIDs all alter the risk profile of adding any vasodilatory supplement to lisinopril. [18]

Choose the appropriate form. Oral liposomal glutathione or sublingual glutathione at 250-500 mg/day represents a lower-risk starting point than IV infusions. Escalate to IV only with prescriber awareness.

Re-check blood pressure at two weeks. A drop of more than 10 mmHg systolic from baseline warrants a call to the prescribing physician.

Report any new symptoms promptly. Dizziness on standing, unusual fatigue, or swelling anywhere on the face or throat should prompt immediate medical evaluation.

What Prescribers Are Saying

The 2017 ACC/AHA Hypertension Guideline states that "patients should be asked about use of herbal and dietary supplements at every visit, as certain supplements may alter blood pressure or interact with antihypertensive medications." [19] This language applies directly to glutathione: not because glutathione is specifically listed as a high-risk supplement in the guideline, but because blood-pressure-affecting supplements as a class require routine disclosure and monitoring.

The National Kidney Foundation's KDOQI Clinical Practice Guidelines for CKD similarly advise providers to assess supplement use in patients on ACE inhibitors, given the potential for additive effects on hemodynamics in patients with already-compromised renal autoregulation. [20]

Summary of Interaction Classification

| Factor | Oral Glutathione | IV Glutathione | |---|---|---| | Pharmacokinetic interaction with lisinopril | None documented | None documented | | Pharmacodynamic interaction (blood pressure) | Theoretical, minor | Possible, clinically relevant | | Evidence level | Indirect; no RCT | Small studies only | | Interaction severity (Natural Medicines) | Minor | Monitor closely | | Action required | Disclose to prescriber, monitor BP | Prescriber clearance recommended |